Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC-PINK:HALB) has partnered with the newly formed Hamden Group, led by Darren Hamans and the Croden family, to enhance sales and distribution of its patented low-dose Naltrexone medication and Vita-Shield-Max™ nutraceutical product. The Hamden Group possesses extensive pharmaceutical experience, aiming to accelerate revenue for HALB. This contract grants Hamden exclusive rights worldwide for sales and marketing. CEO William Hartman notes the significant potential in sales for these products targeting various health conditions, including MS and addiction.
Halberd Corporation (OTC PINK:HALB) executives William A. Hartman and Dr. Mitchell S. Felder discussed transformative research milestones and their implications for healthcare during an interview on The Street Reports. They emphasized how their innovations could significantly impact the treatment of various diseases. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and has filed 22 additional patent applications to enhance stockholder value and attract development partners. For further updates, interested individuals can subscribe via the company's contact page.
Halberd Corporation (OTC PINK:HALB) announced the successful elimination of various antibiotic-resistant bacteria using a unique monoclonal antibody combined with a metallic nanoparticle. This method reportedly kills over 90% of bacteria in less than 20 minutes, a significant improvement over traditional antibiotics that can take up to 10 days. The technology targets Gram-negative bacteria, including E. coli and Salmonella, and the CDC will provide antibiotic-resistant samples for further research. Halberd believes this breakthrough could revolutionize treatment for sepsis and other serious infections.
Halberd Corporation (OTC PINK:HALB) has successfully removed Interleukin-6 (IL-6) from human blood serum in recent laboratory tests. IL-6 is linked to inflammation and diseases like rheumatoid arthritis and certain cancers. Unlike previous methods using laser irradiation on cerebrospinal fluid, this new approach employs a specially engineered antibody bonded to a microbead filter. The CEO highlighted the platform's potential for universal application in treating various diseases. The company has also secured exclusive rights to three patents, enhancing its value for shareholders.
Halberd Corporation (OTC PINK:HALB) announced a strategic alliance with AI Longevity, Inc. and Stem of Hope to create a subsidiary named Extendalife focused on longevity and treatments for Alzheimer's Disease and Cancer. The alliance aims to leverage patented technologies for disease treatment and longevity enhancement.
The team plans to start animal testing by year-end, with expectations for initial feasibility results in improving longevity. Halberd intends to spin off Extendalife as a publicly traded entity, granting shares to current shareholders, enhancing potential shareholder value.
Halberd Corporation (OTC PINK:HALB) has successfully demonstrated the ability to control PD-1 levels in human blood serum during lab tests. This process, which can effectively eliminate PD-1, could empower the body's immune system to target cancer tumors more effectively. The company’s patented technique offers a swift restoration of PD-1 levels, potentially revolutionizing cancer immunotherapy. Both Dr. Mitchell S. Felder and CEO William A. Hartman expressed optimism regarding the implications of these results for safer and more effective cancer treatments.
Halberd Corporation (OTC PINK:HALB) received a significant endorsement from Carl Eller, President of the NFL Retired Players Association, for its innovative treatments targeting Traumatic Brain Injury (TBI) and related neurodegenerative diseases. This endorsement follows Halberd's research showing effective in-vitro elimination of inflammatory cytokines linked to head trauma. Halberd's leadership, including CEO William A. Hartman, expressed optimism for further collaboration with sports organizations. The company holds exclusive rights to multiple patents, enhancing its market value.
Halberd Corporation (OTC PINK:HALB) has established a wholly-owned subsidiary named Halberd Cancer Therapeutics, LTD. This move aims to leverage Halberd's patented extracorporeal technology for developing cancer treatments. Initially staffed by Halberd employees, the subsidiary may eventually evolve into a standalone company, potentially benefiting stockholders through dividends. The company is also progressing on specific cancer antibodies for near-term experimentation, indicating a focus on innovative cancer therapies.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough in Covid-19 treatment, with a proprietary monoclonal antibody that enhances the effectiveness of a leading commercial Covid-19 antibody from 65% to 94%. This antibody is effective against all current SARS-CoV-2 mutations including Omicron. Their research emphasizes the potential for widespread treatment against evolving variants. CEO William A. Hartman mentions ongoing discussions for potential patents stemming from these promising results, which could attract further industry interest.
Halberd Corporation (OTC PINK:HALB) reported significant technical and organizational milestones for Q2 2022, ending June 30. The company added animal testing expertise to enhance its patented process for removing disease antigens. A scientific article is in review for patent protection, while outreach for endorsements from the NFL and NCAA is ongoing. Halberd is exploring FDA authorization for its technology and submitted audited financials to the SEC for OTCQB uplisting. Future plans include animal testing and potential spin-offs of specialized subsidiaries, broadening treatment options for various diseases.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
